Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company’s lead product candidate, XMT-1536, is a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizing the Company’s Dolaflexin platform to deliver an average of 10 to 12 DolaLock payload molecules per antibody.